Septerna, Inc. Common Stock (NASDAQ:SEPN) — Market Cap & Net Worth
Market Cap & Net Worth: Septerna, Inc. Common Stock (SEPN)
Septerna, Inc. Common Stock (NASDAQ:SEPN) has a market capitalization of $1.64 Billion ($1.64 Billion) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6904 globally and #2141 in its home market, demonstrating a 2.86% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Septerna, Inc. Common Stock's stock price $38.44 by its total outstanding shares 45075533 (45.08 Million). Also see SEPN total asset value for a full breakdown of the balance sheet.
Septerna, Inc. Common Stock Market Cap History: 2024 to 2026
Septerna, Inc. Common Stock's market capitalization history from 2024 to 2026. Data shows growth from $1.03 Billion to $1.73 Billion (49.21% CAGR). Also see SEPN operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Septerna, Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.06% | #200 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #780 of 3165 |
Weight: Septerna, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Septerna, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Septerna, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Septerna, Inc. Common Stock stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
27.35x
Septerna, Inc. Common Stock's market cap is 27.35 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $1.03 Billion | $1.07 Million | -$71.80 Million | 960.21x | N/A |
| 2025 | $1.26 Billion | $45.95 Million | -$48.88 Million | 27.35x | N/A |
Competitor Companies of SEPN by Market Capitalization
Companies near Septerna, Inc. Common Stock in the global market cap rankings as of September 17, 2026. Review SEPN tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Septerna, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Septerna, Inc. Common Stock Historical Marketcap From 2024 to 2026
Between 2024 and today, Septerna, Inc. Common Stock's market cap moved from $1.03 Billion to $ 1.73 Billion, with a yearly change of 49.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.73 Billion | +37.88% |
| 2025 | $1.26 Billion | +21.75% |
| 2024 | $1.03 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Septerna, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.64 Billion USD |
| MoneyControl | $1.64 Billion USD |
| MarketWatch | $1.64 Billion USD |
| marketcap.company | $1.64 Billion USD |
| Reuters | $1.64 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Septerna, Inc. Common Stock
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 … Read more